Grover Phulwinder K, Ryall Rosemary L
Urology Unit, Department of Surgery, Flinders Medical Centre, Bedford Park, South Australia 5042, Australia.
Clin Sci (Lond). 2002 Apr;102(4):425-34.
In recent years there has been great interest in the putative role of prothrombin and its activation peptides, especially the urinary form of prothrombin fragment 1, in the pathogenesis of calcium oxalate (CaOx) urolithiasis. Previously, we showed that prothrombin and its activation peptides inhibit CaOx crystallization in inorganic conditions in vitro. The aim of the present study was to determine if this inhibitory activity is retained in undiluted human urine and, therefore, whether it is likely to have any influence under physiological conditions. A secondary objective was to assess the relationship between the structures of the proteins and their inhibitory activities. Prothrombin was purified from Prothrombinex-HT, cleaved with thrombin and the resulting fragment 1 (F1) and fragment 2 (F2) were purified. The purity of each protein was confirmed by SDS/PAGE, and their effects on CaOx crystallization in undiluted ultrafiltered human urine were determined at a final concentration 80.65 nmol/l using Coulter Counter and [(14)C]oxalate analysis. The precipitated crystals were visualized using scanning electron microscopy. The Coulter Counter data revealed that, whereas prothrombin and its activation peptides did not affect the urinary metastable limit and the size of the precipitated particles, F1 did significantly reduce the latter. These findings were corroborated with scanning electron microscopy which also revealed that the reduction in particle size caused by F1 resulted from a decrease in the degree of crystal aggregation, rather than in the size of the individual crystals. The [(14)C]oxalate data showed that none of the proteins added significantly inhibited the mineral deposition. It was concluded that with the exception of F1, which does inhibit CaOx crystal aggregation, prothrombin and its activation peptides do not alter the deposition and aggregation of CaOx crystals in ultrafiltered human urine in vitro. Also, the gamma-carboxyglutamic acid domain of prothrombin and F1, which is absent from thrombin and F2, is the region of the molecules that determines their potent inhibitory effects. The superior potency of F1, compared with prothrombin, probably results from the molecule's greater charge-to-mass ratio.
近年来,凝血酶原及其激活肽,尤其是尿中形式的凝血酶原片段1,在草酸钙(CaOx)尿路结石发病机制中的假定作用引起了极大关注。此前,我们发现凝血酶原及其激活肽在体外无机条件下可抑制CaOx结晶。本研究的目的是确定这种抑制活性在未稀释的人尿中是否依然存在,以及因此它在生理条件下是否可能产生任何影响。第二个目标是评估蛋白质结构与其抑制活性之间的关系。从Prothrombinex-HT中纯化凝血酶原,用凝血酶切割,然后纯化得到的片段1(F1)和片段2(F2)。通过SDS/PAGE确认每种蛋白质的纯度,并使用库尔特计数器和[¹⁴C]草酸盐分析,在最终浓度为80.65 nmol/l的条件下,测定它们对未稀释的超滤人尿中CaOx结晶的影响。使用扫描电子显微镜观察沉淀的晶体。库尔特计数器数据显示,虽然凝血酶原及其激活肽不影响尿液的亚稳极限和沉淀颗粒的大小,但F1确实显著降低了后者。扫描电子显微镜证实了这些发现,其还显示F1导致的颗粒尺寸减小是由于晶体聚集程度降低,而非单个晶体尺寸减小。[¹⁴C]草酸盐数据表明,添加的任何蛋白质均未显著抑制矿物质沉积。得出的结论是,除了确实抑制CaOx晶体聚集的F1外,凝血酶原及其激活肽在体外未稀释的超滤人尿中不会改变CaOx晶体的沉积和聚集。此外,凝血酶原和F1中的γ-羧基谷氨酸结构域(凝血酶和F2中不存在)是决定其强大抑制作用的分子区域。与凝血酶原相比,F1的效力更强可能是由于该分子具有更高的电荷质量比。